Thermo Fisher Scientific Inc (TMO)
Industry Diagnostics & Research
This stock can be held in an Investment ISA and an Investment Account
Sell
$467.88
Buy
$469.88
$3.01 (+0.65%)
Prices updated at 25 Apr 2026, 00:27 EDT
| Prices minimum 15 mins delay
Prices in USD
Thermo Fisher Scientific Inc is a healthcare company. It offers analytical instruments, laboratory equipment, software, services, consumables, reagents and chemicals.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2024 | 2025 |
|---|---|---|
| 42,879m | 44,557m | |
| 17,702m | 18,239m | |
| 7,717m | 8,110m | |
| 18.00 | 18.20 | |
| 6,335m | 6,704m | |
| 11,535m | 11,507m | |
| Sales, General and administrative | 8,595m | 8,732m |
| Interest expenses | 1,390m | 1,419m |
| Provision for income taxes | 657m | 547m |
| Operating expenses | 9,985m | 10,129m |
| Income before taxes | 7,037m | 7,308m |
| Net income available to common shareholders | 6,335m | 6,704m |
| 16.58 | 17.77 | |
| Net interest income | -312m | -426m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | 16.53 | 17.74 |
| Free cash flow per share | 20.2342 | 16.1134 |
| Book value/share | 128.6641 | 135.6063 |
| Debt equity ratio | 0.586085 | 0.671298 |
Balance sheet
Year | 2024 | 2025 |
|---|---|---|
| Current assets | 22,137m | 28,707m |
| Current liabilities | 13,332m | 15,189m |
| Total capital | 78,646m | 89,259m |
| Total debt | 31,275m | 39,385m |
| Total equity | 49,585m | 53,407m |
| Total non current liabilities | - | - |
| Loans | 29,061m | 35,852m |
| Total assets | 97,321m | 110,343m |
| Total liabilities | - | - |
| Cash and cash equivalents | 4,009m | 9,852m |
| Common stock | 381m | 376m |
Cash flow
Year | 2024 | 2025 |
|---|---|---|
| Cash at beginning of period | 8,097m | 4,040m |
| Cash dividends paid | -583m | -636m |
| 7,267m | 6,293m | |
| Investments (gains) losses | -5,841m | -4,047m |
| 4,040m | 9,879m | |
| Net income | - | - |
| 8,667m | 7,818m | |
| -1,400m | -1,525m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.